There has been significant use of digital tools in specialty pharmacy during the COVID-19 pandemic, but it remains to be seen if that move will remain permanent in addition to other offerings, in a less acute setting of care, said Lance Grady, market access practice director, Avalere Health.
There has been significant use of digital tools in specialty pharmacy during the COVID-19 pandemic, but it remains to be seen if that move will remain permanent in addition to other offerings, in a less acute setting of care, said Lance Grady, market access practice director, Avalere Health.
Transcript
How are the digital support tools of the pandemic helping to improve specialty prescription fulfillment and therapy?
We're seeing significant innovation on the pharmacy switch, whether that be through the benefit or above the benefit, we know that e-pharmacy solutions or pharmacy solutions that are on the switch are proliferating. I think the question is going to be to the plans and PBMs [pharmacy benefit managers] and payers as to, does that become flexibility for their members? And does that flexibility for their members move towards their own sort of PBM-owned or plan-coordinated or plan-contracted specialty pharmacy to also offer those types of innovations?
That’s the open question that we still don't know yet. Meaning, does, does a large PBM-owned specialty pharmacy innovate with digital solutions and e-solutions as a supplement to their already rather proven sort of call center with education nurses with benefits specialists and counselors and coordinators and, of course, pharmacists. So, I think that is the still the unanswered question. Do we see the innovation stay sort of in the periphery or do we see it move to large or mid-size specialty pharmacy as a part of a comprehensive offering for plans and our plan members?
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More